COPD Inhaler Comparison Tool
Find Your Ideal Inhaler
Answer these brief questions to see which inhaler best matches your needs and preferences.
Recommended Inhalers
Why this is your best match:
• Matches your
• Average monthly cost:
Key Features
Dosing Frequency
Active Ingredient
Device Type
FDA Approval
Other Options That Might Work For You
Key Considerations
Remember: Always consult your healthcare provider before switching inhalers. They can check your technique and ensure the best treatment for your specific condition.
• Once-daily inhalers generally improve adherence
• Tiova Rotacap is particularly helpful for patients with weak inhalation or limited hand strength
• Combining multiple long-acting bronchodilators offers no additional benefits
Choosing the right inhaler for chronic obstructive pulmonary disease (COPD) or asthma can feel like a gamble, especially when brand names, devices and dosing schedules all differ. This guide lays out a side‑by‑side look at Tiova Rotacap and the most common alternatives, so you can see which option fits your lifestyle, budget and clinical needs.
What is Tiova Rotacap?
Tiova Rotacap is a soft‑mist inhaler that delivers the long‑acting anticholinergic tiotropium bromide. The device uses a rotating capsule to generate a fine aerosol without the need for a propellant, making it easier for patients with limited hand‑strength to inhale the full dose. Each capsule contains 18 µg of tiotropium, intended for once‑daily use.
How Tiova Works and Who Can Use It
Tiotropium blocks muscarinic receptors in the airways, reducing bronchoconstriction and improving lung function for up to 24 hours. It is approved for maintenance treatment of COPD, and in some regions for asthma that is not fully controlled by inhaled corticosteroids alone.
Major Alternatives on the Market
Several other inhalers deliver tiotropium or combine it with additional bronchodilators. Below is a quick snapshot of each, with microdata attached to the first mention.
- Spiriva Handihaler - a traditional dry‑powder inhaler that also delivers tiotropium (18 µg) once daily. It requires patients to load a capsule into the device before inhalation.
- Anoro Ellipta - a combination of umeclidinium (62.5 µg) and vilanterol (25 µg) in a breath‑actuated powder inhaler, taken once daily.
- Tudorza Pressair - delivers aclidinium bromide (340 µg) twice daily via a multi‑dose dry‑powder inhaler.
- Incruse Ellipta - contains umeclidinium (62.5 µg) as a once‑daily long‑acting muscarinic antagonist (LAMA).
- Breo Ellipta - a fixed‑dose combination of fluticasone propionate (100/200 µg) and vilanterol (25 µg) delivering both anti‑inflammatory and bronchodilator effects once daily.
Head‑to‑Head Comparison Table
| Brand (Device) | Active(s) | Dose Frequency | Device Type | FDA Approval Year | Typical UK Cost (per month) |
|---|---|---|---|---|---|
| Tiova Rotacap | Tiotropium 18 µg | Once daily | Soft‑mist cap | 2022 | £34 |
| Spiriva Handihaler | Tiotropium 18 µg | Once daily | Dry‑powder capsule | 2004 | £38 |
| Anoro Ellipta | Umeclidinium 62.5 µg + Vilanterol 25 µg | Once daily | Breath‑actuated DPI | 2013 | £45 |
| Tudorza Pressair | Aclidinium 340 µg | Twice daily | Multi‑dose DPI | 2015 | £40 |
| Incruse Ellipta | Umeclidinium 62.5 µg | Once daily | Breath‑actuated DPI | 2014 | £42 |
| Breo Ellipta | Fluticasone 100/200 µg + Vilanterol 25 µg | Once daily | Breath‑actuated DPI | 2010 | £48 |
Key Decision Factors
When you line up Tiova Rotacap against the alternatives, ask yourself these practical questions:
- Ease of use: The soft‑mist system eliminates the need for a forceful inhalation, beneficial for patients with weak inspiratory flow.
- Dosing schedule: All options except Tudorza Pressair are once‑daily, which tends to improve adherence.
- Clinical efficacy: Large trials (e.g., UPLIFT for tiotropium, IMPACT for combinations) show comparable improvements in FEV1, but combo inhalers add anti‑inflammatory action.
- Side‑effect profile: Dry‑powder inhalers may cause throat irritation; soft‑mist inhalers can feel wetter but usually cause less cough.
- Cost and reimbursement: In the UK, many NHS formularies favour generic tiotropium, but device‑specific pricing can vary.
- Switching considerations: If you move from a capsule‑based device to a DPI, you’ll need a technique check to avoid sub‑optimal dosing.
Practical Tips for Patients Who Want to Switch
Switching inhalers isn’t just a paperwork exercise-it requires a short learning curve.
- Book a quick inhaler technique review with your pharmacist. They can demonstrate the rotating‑cap action of Tiova versus the loading of a Handihaler.
- Mark the first dose on a calendar. Even though Tiova is once‑daily, forgetting a dose can lead to a noticeable dip in breathlessness.
- Watch for a “wet” sensation after the soft‑mist puff; it’s normal and indicates the full dose was delivered.
- If you experience persistent cough, discuss with your GP whether a DPI might be gentler on your throat.
- Check your medication list for duplicate bronchodilators. Combining two LAMAs offers no extra benefit and raises side‑effect risk.
Frequently Asked Questions
Is Tiova Rotacap suitable for asthma?
Tiova is primarily licensed for COPD, but some clinicians prescribe it off‑label for severe asthma when inhaled corticosteroids are insufficient. Always follow your specialist’s advice.
How does the soft‑mist delivery differ from a dry‑powder inhaler?
Soft‑mist creates a fine aerosol using mechanical rotation, so it does not depend on the patient’s inspiratory flow. Dry‑powder inhalers require a rapid, deep breath to pull medication into the lungs.
Can I use Tiova and Spiriva together?
Both contain the same active ingredient, so using them together offers no added benefit and increases the risk of anticholinergic side effects. Choose one LAMA regimen.
What should I do if I miss a dose?
Take the missed dose as soon as you remember, unless it’s almost time for the next scheduled dose. In that case, skip the missed one-don’t double up.
Is Tiova covered by the NHS?
Many Clinical Commissioning Groups list Tiotropium as a first‑line LAMA, but coverage can depend on local formulary decisions and whether the soft‑mist device is deemed clinically necessary.
